Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMG9VHN)

• Drug Name: Depemokimab Drug Info
• Synonyms: GSK3511294

Indication

Disease Entry	ICD 11	Status	REF
Asthma	CA23	Phase 3	[1]

• Cross-matching ID: TTD Drug ID: DMG9VHN

Molecule-Related Drug Atlas

Drug(s) Targeting Interleukin-5 (IL5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Benralizumab	DM7P1J4	Asthma	CA23	Approved	[3]
Mepolizumab	DMW2GEJ	Severe asthma	CA23	Approved	[4]
Reslizumab	DM0AUCH	Severe asthma	CA23	Approved	[5]
GSK3511294	DMWKSFY	Asthma	CA23	Phase 3	[2]
SOPHORICOSIDE	DM4A0NP	Discovery agent	N.A.	Investigative	[6]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-5 (IL5)	TTPREZD	IL5_HUMAN	Antagonist	[2]

References

• [1] ClinicalTrials.gov (NCT04719832) A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype. U.S.National Institutes of Health.
• [2] A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma. Br J Clin Pharmacol. 2022 Feb;88(2):702-712.
• [3] Benralizumab a humanized mAb to IL-5R with enhanced antibody-dependent cell-mediated cytotoxicity a novel approach for the treatment of asthma
• [4] Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563. Drugs R D. 2008;9(2):125-30.
• [5] The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
• [6] Design and synthesis of novel hydroxyalkylaminomethylchromones for their IL-5 inhibitory activity. Bioorg Med Chem. 2010 Jul 1;18(13):4625-9.